EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ 18 F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials

Jin Uk Heo, Santosh Rao, Herbert B Newton, Afshin Dowlati, Raymond F Muzic, Arash Kardan iD

Integrative Cancer Therapies · 2026

DOI: 10.1177/15347354251410182 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Integrative Cancer Therapies, 2026. Verfasst von Jin Uk Heo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Case Western Reserve University and University Hospitals Cleveland Medical Center, OH, USA. Hauptthemen laut MEDLINE: Plant Extracts, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Withania. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ReHeva Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Withania somnifera (WS), commonly known as ashwagandha, has been used in the traditional medical system of India. It has shown significant activity against numerous solid tumor varieties in pre-clinical in vitro and in vivo studies. This study focuses on RH324 (ReHeva Biosciences, Columbus, OH), a pharmaceutical-grade formulation derived from WS, which has received FDA allowance for clinical development as a botanical drug in the treatment of cancer.

Methods

A phase 1 open label dose ranging study of oral RH324 in advanced non-small cell lung cancer (NSCLC) was conducted. The primary endpoint of the study was assessment of short-term safety and tolerability. An exploratory aim was assessment of RH324’s anti-neoplastic effects as measured by changes in tumor metabolism using [ 18 F]-labeled 2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT scans performed before and after completing a 28-day RH324 monotherapy regimen. A total of 9 patients were enrolled, 5 of which completed the trial, including imaging, and were evaluable.

Results

All study safety and tolerability primary endpoints were met. Analysis revealed notable response rates across different SUV parameters (SUV max , SUV mean , and SUV peak ) and there were no new metastatic lesions identified, further supporting RH324’s anti-neoplastic effects.

Conclusion

RH324 was safe and well tolerated as a monotherapy in advanced NSCLC. FDG-PET/CT provided a novel methodology as a short-term metabolic endpoint with an in vivo biomarker assessment of potential clinical efficacy using a metabolic surrogate of disease activity. This approach offered deeper insights into tumor metabolism and heterogeneity, underscoring the potential of RH324’s anti-neoplastic effects in treating refractory NSCLC. Clinical Trial Registration: ClinicalTrials.gov, Identifier: NCT05580172, Registered on October 17, 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plant ExtractsLung NeoplasmsCarcinoma, Non-Small-Cell LungWithaniaHumansMaleFluorodeoxyglucose F18Plant LeavesFemaleMiddle AgedPositron Emission Tomography Computed TomographyAgedAdultBiomarkers, Tumor

Stichwörter der Autor:innen

FDGWithania somniferaintegrative oncologylung cancerphase 1 human trialpositron emission tomography

Substanzen

Plant ExtractsFluorodeoxyglucose F18Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiology, Case Western Reserve University and University Hospitals Cleveland Medical Center, OH, USA.
  • Department of Biomedical Engineering, Case Western Reserve University and University Hospitals Cleveland Medical Center, OH, USA.
  • Seidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Baylor College of Medicine, Houston, TX, USA.

ORCID-Profile: Arash Kardan

Förderung

  • ReHeva Biosciences

Zitieren

APA

Heo, J. U., Rao, S., Newton, H. B., Dowlati, A., Muzic, R. F., & Kardan, A. (2026). Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ 18 F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integrative Cancer Therapies. https://doi.org/10.1177/15347354251410182

Vancouver

Heo JU, Rao S, Newton HB, Dowlati A, Muzic RF, Kardan A. Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ 18 F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integrative Cancer Therapies. 2026. doi:10.1177/15347354251410182

BibTeX
@article{Heo2026,
  author = {Heo, Jin Uk and Rao, Santosh and Newton, Herbert B and Dowlati, Afshin and Muzic, Raymond F and Kardan, Arash},
  title = {Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ 18 F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials},
  journal = {Integrative Cancer Therapies},
  year = {2026},
  doi = {10.1177/15347354251410182}
}
Kostenlos starten →